Urinary Kallidinogenase for stroke and type 2 diabetes
Part of Brain & nervous system, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests if a medication called Urinary Kallidinogenase can help people who have had a stroke and also have type 2 diabetes. It may improve recovery by increasing blood flow to the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You had a stroke caused by a blood clot, and the stroke affects a large or medium area of your brain.
- You also have type 2 diabetes, diagnosed by a doctor.
- You started having stroke symptoms less than 48 hours ago.
- This is your first stroke, or if you had a previous stroke, you had no disability before this one.
- Your stroke symptoms are moderate, with a score between 6 and 20 on a standard stroke scale.
- You or your legal representative can sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called urinary kallidinogenase to see if it helps people who have had a stroke caused by a large artery in the brain becoming narrowed or blocked. It is for those who can be treated within 48 hours of symptoms starting.
This trial tests a drug called Human Urinary Kallidinogenase to see if it can help people recover better after a recent stroke caused by a blockage in the front part of the brain. It is for patients who have mild to moderate symptoms and can start treatment within 2 days of the stroke.
This trial tests whether a medicine called human urinary kallidinogenase can reduce inflammation after a stroke. It may help people who have had a first or recent stroke and have certain levels of disability.
This trial tests whether adding a drug called human urinary kallidinogenase to standard clot-busting therapy with reteplase improves outcomes for people having a first or recurrent ischemic stroke. It is designed for patients who can start treatment within 4.5 hours of symptoms and have moderate stroke severity.
This study tests whether adding a drug called human urinary kallidinogenase to standard clot-removal therapy helps people recover better after a large-vessel stroke. If you qualify, you would receive the drug or a placebo by IV along with the procedure, and doctors will monitor your recovery.
This trial tests if adding a drug called human urinary kallidinogenase (HUK) can improve recovery for people who have had a stroke and already received clot-busting medicine or a procedure to remove the clot. The goal is to see if it helps reduce disability after a stroke.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.